Fezolinetant, a non-hormonal treatment for menopausal hot flushes, will be added to the HRT formularies for EMIS and SystmOne in line with NICE guidance. These will be updated to include clear notes on indications, cautions (such as previous breast cancer), and monitoring requirements, ensuring prescribers have the latest information and guidance for safe use.